Document is current
Any future updates will be listed below
-
Authors
Björnsson, Robert A
Sigurdsson, Sigurdur Sölvi
Arnarson, Dagur Tjörvi
Logason, Egill
Björnsson, Einar Stefan https://orcid.org/0000-0002-8392-0632
- License Information
-
More Information
Article History
Accepted: 20 February 2025
First Online: 12 March 2025
Declarations
:
: No funding was obtained for this work.
: Following authors have no conflicts of interest to declare (RAB, SSS, DTA, EL). Einar Stefan Björnsson is on hepatic safety committees for Novo Nordisk on studies on semaglutide, Novartis, for studies on remibrutinib, Sanofi, studies on tolebrutinib, Inventiva, studies on Lanifibranor, Kainos Medicine, studies on KM-819 drug candidate. Einar Stefan Björnsson is an Editorial Board member of Drug Safety. Einar Stefan Björnsson was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions.
: The study was approved by the ethical committee of the Landspitali University Hospital (LSH-16-12/3/2024).
: Not applicable.
: Not applicable.
: The authors can provide availability of data on request.
: Not applicable.
: RAB: data collection, data analysis, drafted the first version of the manuscript. SSS, DTA, EL: data analysis, critical review of the manuscript. ESB: design of the study: study conceptualization, data analysis, critical review of the manuscript. All authors read and approved the final version.
